A systematic review and economic model of the effectiveness and ...

TABLE 27 Results for hyperactivity [MPH high dose (>30 mg/day) plus non-drug intervention versus non-drug intervention]
Study Scale MPH high dose + non-drug: Non-drug: mean (SD) Mean difference
mean (SD)
6–12 years
Schachar, 1997 86 MD (95% CI)
IOWA-C (hyperactivity) (parents) 1.2 (0.7) 1.3 (0.7) –0.10 (–0.33 to 0.13)
IOWA-C (hyperactivity–inattentiveness) (teachers) 0.9 (0.7) 1.7 (0.7) –0.80 (–1.05 to –0.55)
TIP (hyperactivity–impulsiveness) (teachers) 0.8 (0.7) 1.3 (1.1) –0.90 (–1.29 to –0.51)
TIP (hyperactivity–impulsiveness) (parents) 1.2 (1.1) 0.9 (0.9) 0.20 (–0.22 to 0.62)
CTRS (hyperactivity) 0.8 (0.4) 1.5 (0.6) –0.70 (–0.84 to –0.56)
CPRS (hyperactivity) 0.6 (0.3) 0.8 (0.4) 0.20 (0.11 to 0.29)
Home Hyperactivity Scale (parents) 1.8 (0.51) 2.4 (0.86) 0.20 (–0.15 to 0.55)
Klein, 1997 65
Lower scores represent a better behavioural outcome.
CPRS, Conners’ Parent Rating Scale; CTRS, Conners’ Teacher Rating Scale; TIP, Telephone Interview Probe.
© Queen’s Printer and Controller of HMSO 2006. All rights reserved.
TABLE 28 ER-MPH low dose (≤ 20 mg/day) plus non-drug intervention versus non-drug intervention
Health Technology Assessment 2006; Vol. 10: No. 23
Study Design Intervention – N Age Duration Core outcomes
(years) (weeks)
Administered once daily
Pelham, 1987 77 C (3×) Sustained-release MPH (Slow Release Ritalin, 6.5–11 7 Core: no hyp; Abbreviated Conners’ Rating Scale (teacher
SR-20) (20 mg/day, o.d.) vs behaviour rating)
modification (STP, 7 weeks) – 13 QoL: not reported
AE: Side Effects Checklists (parents, teachers, counsellors)
Pelham, 199078 C (5×) Sustained-release MPH (Slow Release Ritalin, 8.1–13.2 8 Core: no hyp; Abbreviated Conners’ Rating Scale (teachers
SR-20) (20 mg/day, o.d.) vs behaviour and counsellors)
modification (STP, 8 weeks) – 22 QoL: not reported
AE: Side Effects Checklists (parents, teachers, counsellors)
C, crossover trial (number of crossovers); STP, Summer Treatment Programme.
51